Compare Recursion Pharmaceuticals Inc (RXRX) vs United Parcel Service Inc (UPS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs United Parcel Service Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $4.21 (market cap $2.14B), while United Parcel Service Inc trades at $94.48 (market cap $80.08B). The key difference: United Parcel Service Inc is far larger — about 37.4× Recursion Pharmaceuticals Inc's market cap, and United Parcel Service Inc pays a 6.97% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Recursion Pharmaceuticals Inc for 22 Days and United Parcel Service Inc for 141 Days on average.
| RXRX | UPS | |
|---|---|---|
Market Cap | $2.14B | $80.08B |
Volume | 30,789,535 | 6,706,833 |
Sector | Health | Industrials |
52-Week High | $6.79 | $120.00 |
52-Week Low | $2.84 | $82.87 |
Typical Hold Time | 22 Days | 141 Days |
Enterprise Value | $1.66B | $104.10B |
Dividend Yield | — | 6.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $4.05, down 5.15% today, with a bullish technical signal from moving averages. The company reported revenue of $74.26M in 2025 but a net loss of $644.76M, with negative profit margins. Recent news highlights strategic AI partnerships, including an extended data license with Tempus AI, aiming to fuel long-term growth despite current financial challenges.
The outlook remains speculative; the stock offers exposure to AI-driven drug discovery through a growing pipeline and partnerships, but high cash burn and lack of profitability pose significant risks. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for future catalysts tempered by near-term financial weakness.
UPS stock trades at $92.28, down 0.89% amid bearish technical signals and mixed fundamentals. The company maintains strong profitability with 29.66% ROE and has beaten earnings estimates for three consecutive quarters. Recent developments include the launch of UPS Secure Commerce and an exclusive TikTok Shop partnership, while facing headwinds from fuel costs and volume pressures. Analyst consensus remains positive with a $118.67 price target representing 29% upside potential.
The investment case balances attractive valuation metrics (P/E 17.5, P/S 0.89) against declining revenue trends and competitive threats. The 7% dividend yield provides income support, but investors face risks from margin compression and Amazon competition. Wall Street sentiment leans bullish despite recent price weakness, with improving domestic margins seen as the key catalyst.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About United Parcel Service Inc
United Parcel Service, Inc. (UPS) delivers packages and documents throughout the United States and in other countries and territories. The Company also provides global supply chain services and less-than-truckload transportation, primarily in the US UPS's business consists of integrated air and ground pick-up and delivery network
Read more on UPS →
